



Alzinova engages Erik Penser Bank as liquidity provider

Alzinova AB has entered into an agreement with Erik Penser Bank to act as liquidity provider in Alzinova's share from November 1, 2023.

The liquidity provision assignment is offered in accordance with the rules of Nasdaq First North Growth Market and means that the liquidity provider continuously quotes a buy and sell volume corresponding to at least SEK 15,000, with a maximum spread of 3% between the bid and ask price. The purpose of the agreement is to promote liquidity in the trading of the share. The agreement and the trading of the liquidity provider will start from 1 November 2023.

For more information, please contact:

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments

Alzinova engages Erik Penser Bank as liquidity provider